Suspect DSCSA Product at Receiving
A pharmacy receives a sealed case of adalimumab pens from a wholesaler. The invoice lists 6 pens; the case label has a 2D barcode, but the pharmacy’s scanner cannot decode it. One pen has a broken tamper seal and a different lot number printed on the carton than on the pen. The wholesaler’s customer service says ‘just dispense it; the product is fine.’ A patient with rheumatoid arthritis is waiting for the first dose, and the pharmacy has no other stock. The pharmacist must decide whether to dispense the intact pens, quarantine the entire case, or return only the damaged pen. The refrigerator has a continuous temperature log; the alarm did not sound.
1. Is the product suspect, and may the pharmacist dispense the intact pens?
Read the worked answer
The product is suspect. A broken tamper seal, a carton-pen lot mismatch, and an undecodable 2D barcode are exactly the kind of anomalies that require quarantine. The pharmacist cannot rely on the wholesaler's verbal assurance or on the temperature log alone. The intact pens are also part of the same case and cannot be assumed unaffected until the investigation is complete. Dispensing any pen would risk patient harm and violate DSCSA verification obligations.
2. What DSCSA and recordkeeping steps should the pharmacist take?
Read the worked answer
- Quarantine the entire case, including the intact pens, in a secured area labeled suspect.
- Do not return the product to saleable inventory and do not dispense it.
- Investigate by checking the transaction history, lot numbers, and product identifier; contact the wholesaler and manufacturer.
- Notify the immediate trading partners as required; if the product is illegitimate, notify FDA and appropriate authorities.
- Document the anomaly, quarantine, notifications, and final disposition.
3. How should the pharmacist address the waiting patient’s care?
Read the worked answer
The patient should not receive the suspect product. The pharmacist should explain that the product cannot be used, contact the prescriber about an alternative source or delay, and document the interruption in therapy. If the patient needs urgent treatment, the pharmacist should help arrange a transfer to a pharmacy with verified stock. Patient safety and DSCSA compliance take priority over the waiting patient or the desire to avoid a return.